Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Themes AI

The Future of Longevity: AI and Nanorobots to Radically Extend Life

by Team Lumida
June 25, 2024
in AI, Health and Longevity
Reading Time: 3 mins read
A A
0
person holding black and white microscope

Photo by Jaron Nix on Unsplash

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

  1. AI-driven drug discovery could drastically cut down clinical trial times.
  2. Medical nanorobots may revolutionize immune systems by the 2030s.
  3. By 2040s, mind-backup systems might allow near-immortality.

What Happened?

Futurist Ray Kurzweil claims that AI will revolutionize drug discovery and medical interventions by the end of the 2020s. He believes biological simulators will soon generate crucial safety and efficacy data in hours, not years.

This shift could lead to faster drug approvals and save countless lives. Kurzweil also predicts that medical nanorobots will emerge in the 2030s, vastly enhancing our immune systems and treating metabolic diseases. By 2040s, he envisions mind-backup systems that could essentially render death obsolete.

Why It Matters?

These advancements could disrupt traditional medical models and extend human lifespans dramatically. Faster drug approvals would mean quicker access to lifesaving treatments. Medical nanorobots could address diseases that our natural immune systems can’t, such as cancer and neurodegenerative disorders.

The potential to back up our minds might lead to radical life extension, fundamentally changing the concept of mortality. Investors should note the profound implications for the healthcare and biotech sectors, which could experience exponential growth.

What’s Next?

Expect increased investment in AI-driven pharmaceutical research and biotech firms focused on nanotechnology. Regulatory landscapes will evolve to accommodate simulated trials, despite potential bureaucratic resistance. By the mid-2040s, mind-backup technologies will likely face ethical and security challenges, but Kurzweil is optimistic about overcoming these hurdles.

As these technologies become mainstream, they will likely follow the trajectory of the cell phone—starting expensive and exclusive, but eventually becoming widely accessible.

Source: Fortune Well
Tags: AI-driven drug discoverymedical nanorobotsmind-backup systemsRay Kurzweil
Previous Post

Bitcoin Crashes to $62K: What’s Behind the $150M Liquidation?

Next Post

TikTok Ban Could Dent Oracle’s Earnings: What Investors Need to Know

Recommended For You

Nvidia Posts $81.6 Billion Quarter — Up 85% — as the Agentic AI Era Goes Parabolic

by Team Lumida
15 hours ago
Nvidia’s AI Demand Surge: Hon Hai Ramps Up Server Production

Nvidia shattered expectations with record Q1 revenue of $81.6 billion and net income of $58.3 billion, driven by exploding demand for AI agents and data-center compute. CEO Jensen...

Read more

Anthropic Is on Pace for Its First Profitable Quarter — With $10.9 Billion in Q2 Revenue

by Team Lumida
15 hours ago
Pentagon–Anthropic Feud Escalates as AI Policy Clash Threatens Defense Contracts

Anthropic expects $10.9 billion in Q2 revenue — more than double Q1 — and $559 million in operating profit, its first profitable quarter ever, driven by explosive enterprise...

Read more

OpenAI Is Filing for Its IPO — Possibly as Soon as This Friday

by Team Lumida
1 day ago
OpenAI Hack: Why AI Companies Are Prime Targets for Cyberattacks

OpenAI is working with Goldman Sachs and Morgan Stanley on a confidential IPO filing it could submit as early as Friday, targeting a public debut as soon as...

Read more

Meta’s 8,000 Layoffs Are Underway — and It’s Already Tracking Employee Keystrokes to Train AI

by Team Lumida
1 day ago
a white square with a blue logo on it

Meta began cutting roughly 8,000 jobs Wednesday while simultaneously moving 7,000 workers into AI roles — the most sweeping restructuring in the company's history, funded by eliminating positions...

Read more

Anthropic Gives Mythos Users the Green Light to Share Cyber Threat Intelligence With Each Other

by Team Lumida
3 days ago
Pentagon–Anthropic Feud Escalates as AI Policy Clash Threatens Defense Contracts

Anthropic has updated its policies to allow users of its Mythos platform to share cyber threat intelligence with third parties, a significant shift in how AI-assisted security research...

Read more

Jury Unanimously Rejects Musk’s Claims Against OpenAI — Clearing Path to IPO

by Team Lumida
3 days ago
Major Tech Platforms Face Malaysian Licensing Deadline as X and Google Hold Out

After less than two hours of deliberation, a nine-person jury ruled that Elon Musk's lawsuit against OpenAI and Sam Altman was filed after the statute of limitations expired,...

Read more

Google and Blackstone Are Building a $5 Billion AI Cloud Company Together

by Team Lumida
3 days ago
China Stimulus: Enough to Sway Markets?

In one of the largest AI infrastructure deals of the year, Google and Blackstone are jointly launching a new cloud company with $5 billion in equity to capture...

Read more

Meta Moves 7,000 Employees Into AI Roles Days Before Cutting 8,000 More

by Team Lumida
3 days ago
a white square with a blue logo on it

Meta is simultaneously reassigning 7,000 workers into AI-focused groups and preparing to lay off roughly 8,000 employees on Wednesday — the largest restructuring in the company's history, designed...

Read more

GLP-1 Weight-Loss Drugs Are Triggering Rapid Muscle Loss — and Doctors Are Sounding the Alarm

by Team Lumida
4 days ago
GLP-1 Weight-Loss Drugs Are Triggering Rapid Muscle Loss — and Doctors Are Sounding the Alarm

As 13 million Americans take GLP-1 drugs like Ozempic and Mounjaro, a growing body of research warns the drugs can cause up to 10% lean muscle loss —...

Read more

Morgan Stanley’s Wilson: Bond Rout Threatens AI-Driven Stock Rally — But 12-Month Target Raised to 8,300

by Team Lumida
4 days ago
Morgan Stanley Q2 2024 Earnings Summary

Morgan Stanley's Mike Wilson warns a bond market correction could trigger the first meaningful equity pullback since late March — while simultaneously raising his 12-month S&P 500 target...

Read more
Next Post
a red cube with white text

TikTok Ban Could Dent Oracle's Earnings: What Investors Need to Know

a person holding a phone

AI and Crypto Shakeup: Nvidia and Bitcoin's Massive Drops Explained

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

a computer screen with a bunch of data on it

Retail Investors Pour $67 Billion into U.S. Stocks as Institutional Giants Pull Back

March 25, 2025
Tech Giants Plan to Skirt Trump’s $100,000 H-1B Fee

Tech Giants Plan to Skirt Trump’s $100,000 H-1B Fee

February 11, 2026
Goldman’s Big Bet on Wealth Lending: Doubling Down on the Ultra-Rich

Goldman’s Big Bet on Wealth Lending: Doubling Down on the Ultra-Rich

June 14, 2024

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto data centers Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Intel Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018